The Oncotype DX assay is one of the molecular tests that provide predictive and prognostic information to breast cancer patients with estrogen receptor (ER)-positive and node-negative disease. This study evaluates the association of Forkhead-box protein A1 (FOXA1) and GATA-binding protein 3 (GATA3) expressions with Oncotype DX recurrences scores in 77 cases of patients with ER-positive node-negative breast carcinomas diagnosed at Indiana University. The data were correlated with patient age, tumor size, histologic type, ScarffBloom-Richardson score, histologic grade, and progesterone receptor status. The median FOXA1 and GATA3 scores were 240 and 200, respectively. The Oncotype DX recurrence scores were low in 57%, intermediate in 30%, and high in 13% of cases. FOXA1 expression correlated negatively with Oncotype DX recurrence scores (P ¼ 0.004), and histologic type (P ¼ 0.0004). Oncotype DX recurrences score also correlated negatively with progesterone receptor (P ¼ 0.035) with 100% of progesterone receptor-negative cases having high or intermediate Oncotype DX scores. FOXA1 and GATA3 expressions correlated positively (P ¼ 0.014). The correlation between FOXA1 expression and Oncotype DX recurrence scores remained significant after adjusting for multiple comparisons and controlling for confounders such as histological type, grade, and progesterone receptor. A statistically significant correlation between the Oncotype DX recurrence scores and FOXA1 expression in our diverse cohort of ER-positive breast cancer patients was observed. We propose that this may represent a more cost-effective strategy to further risk stratify patients with good prognosis in whom chemotherapy may be omitted. To confirm these findings, further studies in a larger cohort of patients are warranted.
In this era of personalized medicine, there has been a proliferation of molecular tests in breast cancer to predict response to systemic therapy and also to offer prognostic information to patients. Several multigene prognostic assays are either currently available or are in development. The Oncotype DX recurrence assay (Genomic Health, Redwood, CA, USA) is one of the major commercially available prognostic tools licensed for use in the United States in patients with node-negative estrogen receptor (ER)-positive breast cancer. 1 It assists clinicians in predicting the likelihood of recurrence as well as predicts the benefit of adjuvant systemic chemotherapy given in conjunction with hormonal manipulation. 2 It is a reverse transcription-polymerase chain reaction assay that examines the expression of 16 cancerrelated genes (Ki67, STK15, survivin, CCNB1, MyBL2, MMP11, CTSL2, GRB7, Her2/neu, GSTM1, CD68, BAG1, ER, progesterone receptor [PR] , BCL2, and SCUBE2) and 5 reference genes from malignant breast specimens. The expression pattern of each of these genes is tabulated using an equation and a recurrence score is assigned to each case. Among these genes, higher expression levels of ER, PR, BCL2, SCUBE2, GSTM1, and BAG1 reduce the recurrence score (negative values) whereas higher expression levels of remaining genes increase the recurrence score. Although a direct relationship between molecular subtypes and recurrence score has not been investigated, indirect evidence suggests that patients with low recurrence score belong to luminal A subtype. 3 Patients in the high recurrence score category benefit from adjuvant chemotherapy; however, those with a low recurrence score tend to have a lower likelihood of benefiting from cytotoxic chemotherapy and are a potential group in whom chemotherapy can be avoided. Other assays, either available or in development, include the 70 gene profile/MammaPrint, Pro-Ex Br, wound response gene signature, intrinsic subtypes, Mammostrat, 2 gene ratio, MapQuant DX, and the invasiveness gene signature. [4] [5] [6] [7] [8] [9] [10] Most of these assays, including the Oncotype DX assay, are expensive and have not been prospectively validated. In addition, some of these assays require the use of fresh tissue for processing. It therefore becomes necessary to develop novel strategies for providing both prognostic and predictive information to patients in a more cost-effective and efficient manner using techniques that can be clinically reproducible and prospectively validated. One such strategy could be to develop immunohistochemical assays that can identify luminal A subtype/low recurrence score tumors in which cytotoxic chemotherapy can safely be avoided.
The transcription factor network composed of ER, Forkhead-box protein A1 (FOXA1), and GATAbinding protein 3 (GATA3) controls the gene expression pattern in luminal subtype A breast cancers. [11] [12] [13] This class of breast cancers tends to be ER-positive, PR-positive, Her2/neu-negative, well differentiated; therefore, it may correspond to the majority of cases sent for Oncotype DX testing in clinical practice. FOXA1 is a forkhead family transcription factor that interacts with cis-regulatory regions in chromatin and enhances the interaction of ERa with chromatin.
14 It is required for optimum expression of approximately 50% of ER-regulated genes and estrogen-induced cell proliferation. 14, 15 In mammary epithelial cells, FOXA1 expression is positively regulated by GATA3, 12 which is a lineage-restricted transcription factor essential for the differentiation of mammary luminal progenitor cells. 12, 16 Therefore, luminal epithelial cells that express ER and GATA3 are expected to express the highest levels of FOXA1 in the mammary gland. Indeed, FOXA1, ER, and GATA3 are each expressed in a specific subpopulation of normal luminal epithelial cells and are likely coexpressed. 12, 17, 18 As FOXA1, GATA3, and ER coexist in a network regulating luminal subtype A breast carcinomas, we hypothesized that tumors expressing FOXA1 and/or GATA3 will have a low recurrence score. We therefore investigated the correlation of FOXA1 and GATA3 expressions with the recurrence score in breast cancers that were tested by Oncotype DX. To our knowledge, this is the first attempt to correlate the recurrence score with novel molecular markers.
Materials and methods
The study population comprised 77 consecutive cases of invasive breast cancers that had Oncotype DX testing performed on tumor blocks between 2005 and 2008 from the pathology department of the Indiana University and affiliated hospitals. Oncotype DX was performed on paraffin-embedded tumor samples at Genomic Health Laboratories as described earlier. 1 All patients had ER-positive and node-negative invasive breast cancers. The slides were reviewed by a breast pathologist and graded according to the modified Nottingham grading criteria. The study was approved by the Indiana University School of Medicine Institutional Review Board.
Her2/neu, ER, and PR status were obtained from the pathology reports and verified from the Oncotype DX report. ER and PR immunohistochemical staining at our institutions is performed using 1D5 mouse monoclonal and clone PR636 (Dako, Carpenteria, CA, USA) antibodies for ER and PR, respectively. Her2/neu protein is analyzed using the Hercept test (Dako) using standard FDA-approved methods. A positive result was indicated by 3 þ immunoreactivity (overexpression) or fluorescence in situ hybridization amplification.
Expression of FOXA1 was analyzed using goat antihuman FOXA1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) by IHC. After dewaxing and hydration, 4 mm sections from formalinfixed paraffin embedded tissue were treated with target retrieval (Dako, pH 6.0), in a pressure cooker. Endogenous peroxidase activity was blocked by hydrogen peroxide for 10 min. The slides were then incubated with polyclonal goat FOXA1 antibody (1:200; Santa Cruz Biotechnology) for 1 h at room temperature. The sections were incubated with donkey antigoat horseradish peroxidase polymer conjugate (Jackson Labs, West Grove, PA, USA) according to the manufacturer's instructions. The stain was developed using diaminobenzidine (DAB) plus (Dako, Glostrup, Denmark) and hematoxylin QS (Vector Laboratories, Burlingame, CA, USA) counterstain. To verify the specificity of staining, nonimmune goat serum and PBS-negative controls were used. Similar procedure was used for GATA3 using goat antihuman GATA3 antibody (1:100; Santa Cruz Biotechnology). Percentage of staining was categorized as '0%' if there was no nuclear expression to a maximum score of '100%'. Intensity was scored as 1 þ , 2 þ , and 3 þ for weak, moderate, and strong staining, respectively.
Percentage (P) and intensity (I) of nuclear expression for FOXA1 and GATA3 were multiplied to generate a numerical expression score (S ¼ P Â I). The maximum expression was therefore 300, whereas the minimum was 0. A cutoff of 30 was used for categorizing FOXA1 as positive. 17 Table 1 . Twenty-one of 77 cases (27%) analyzed were o50 years of age; the median age was 55 years (mean, 55; range 29-77). Median tumor size was 1.4 cm (mean, 1.6 cm; range, 0.3-7 cm). Invasive ductal carcinomas accounted for 75% of tumors, whereas 9% were lobular, and 16% were mixed. Forty percent of tumors were histologic grade I, 46 and 14% were grades II and III, respectively. PR expression was absent in 11 (14%) cases. Caucasians accounted for 82% of cases vs 5% African-Americans. Race was undocumented in 13%.
Oncotype DX recurrence scores were low, intermediate, and high in 57, 30, and 13% of cases, respectively; the median recurrence score was 16. Oncotype DX recurrence score categories did not differ by age or tumor type. However, there was a significant difference across the categories when compared with tumor size and tumor grade including Scarff-Bloom-Richardson score. High Oncotype DX recurrence score category showed a higher median Scarff-Bloom-Richardson score. Oncotype DX recurrence score also correlated negatively with PR (P ¼ 0.035) with 100% of the PR-negative cases having a high or intermediate Oncotype DX score. Table 2 shows the relationship between the variables and Oncotype DX recurrence score categories.
The median FOXA1 score was 240 (range, 0-300). FOXA1 score negatively correlated with the recurrence score both using a categorical (Po0.0001) and continuous variable (P ¼ 0.004). A lower mean FOXA1 score was observed in high Oncotype DX recurrence score category (Figure 1a and b 
Discussion
Approximately, 50% of women with a new breast cancer diagnosis in the United States have ERpositive disease without regional lymph node metastasis. 19 The current magnitude and public health burden of early-onset breast cancer underscore the necessity of further understanding the optimal management for this group of patients. Further recurrence risk reduction strategies before or after surgical treatment include the use of neoadjuvant or adjuvant therapy with hormonal manipulation or cytotoxic chemotherapy. Administration of tamoxifen in women with ER-positive disease reduces the annual breast cancer mortality by approximately 30% irrespective of the use of chemotherapy or age. 20 The decision to administer adjuvant chemotherapy in this group of women by estimating the absolute benefit to be derived from such therapies becomes critically important given the significant improvements seen with hormonal therapies alone. In addition, chemotherapy is associated with both long-and short-term toxicities such as the risk of secondary malignancies, significant healthcare costs, and loss of productive time. Traditionally, adjuvant chemotherapy decisions are made using clinicopathological prognostic factors such as tumor size, grade, regional lymph node status, age, or the decision tools/guidelines based on these factors, e.g., Adjuvant! Online, National Comprehensive Cancer Network (NCCN), and St Gallen's guidelines. [21] [22] [23] More recently, genetic profiling is being incorporated into clinical oncology practice to guide adjuvant therapy decisions. Oncotype DX recurrence score assay is one of the diagnostic tools recently approved in the United States for use in breast cancer patients with node-negative ER-positive tumors to guide adjuvant chemotherapy decisions. Although such tools may revolutionize the care of breast cancer patients by attempting to tailor therapy to each individual's molecular profile, they are expensive and currently lack prospective validation. Owing to these concerns, several investigators have attempted to use clinicopathologic features to predict the recurrence score. In a population-based cohort of 300 early-stage breast cancer patients, Wolf et al 24 determined that neither standard clinicopathologic features nor commonly used clinical guidelines reliably predicted the recurrence score. Another study by Flanagan et al 25 suggested that the recurrence score correlated with histopathologic variables such as tubule formation, nuclear grade, mitotic count, ER status, PR status, and Her2/neu status. A hypothesis of the observed discrepancy may be that the molecular biology of these tumors may not correlate completely with standard histopathologic variables such as those that have been tested. Given that Oncotype DX evaluates prognosis by more formal molecular risk estimation in ER-positive breast cancers, 1 FOXA1 and GATA3, which contribute to the hormonal control of gene expression pattern in this group of patients in conjunction with ER, may in fact correlate with the recurrence score.
In this study, we report on the correlation between FOXA1 and GATA3 expression levels and the Oncotype DX 21-gene recurrence scores in 77 consecutive breast cancer patients with ER-positive node-negative disease in a diverse population from different hospital settings. We did indeed find a statistically significant negative correlation between the recurrence scores and FOXA1 expression. GATA3 expression also correlated negatively with the recurrence scores; however, this did not reach statistical significance, possibly because of our limited sample size.
Another interesting observation of our study was that the proportion of patients with an intermediate recurrence score was higher than that reported in the analysis of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 clinical trial (29.9% vs 22%). 1 Similarly, the proportion of individuals with a high recurrence score was much lower in our cohort than in the patients on B-14 (13% vs 27%). We also observed similar findings in the studies evaluating the influence of Oncotype DX recurrence score on decision making and its association with clinicopathologic features. [24] [25] [26] [27] Thus, our study likely represents a more 'real-life' distribution of Oncotype DX risk categories in patients with early-stage ER-positive disease.
We are not suggesting that patients with earlystage ER-positive breast cancer should currently be evaluated for FOXA1 and GATA3 expressions rather than the Oncotype DX multigene diagnostic assay; indeed our study does have certain limitations such as limited sample size, lack of prospective validation, and followup data. We do, however, suggest that if other cost-effective and reproducible techniques for providing prognostic information to patients and clinicians become available, then they ought to be investigated in greater depth for a possibility of replacing expensive molecular profiles. This becomes particularly critical in areas where Oncotype DX testing is not available or in individuals who may not have ready access to the test for a variety of reasons. To our knowledge, this is the first study correlating novel transcription factors and other clinicopathologic characteristics with the Oncotype DX recurrence scores. Although our data need to be reproduced in a larger cohort, this concept may indeed represent a novel alternate way to further stratify breast cancer patients to determine which patient might be at a lower risk of recurrence and therefore avoid chemotherapy in such patients.
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